MARAVAI LIFESCIENCES HOLDINGS, INC.

Listed Company

MRVICIK 0001823239NasdaqAcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$185.74M

Net Income

$-130.77M

Total Assets

$770.58M

Equity

$212.38M

Shares Out

—

Op. Cash Flow

$-57.57M

Business

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products and services to enable development of drugs, therapeutics, vaccines, and diagnostics. The company offers complex nucleic acids (including mRNA with proprietary capping and tail-modification technologies), custom enzymes, oligonucleotides, nucleoside triphosphates, and mRNA manufacturing services through its TriLink segment, and biologics safety testing products including host cell protein detection assays, impurity detection kits, and viral clearance prediction tools through its Cygnus segment. Maravai serves biopharmaceutical companies, biotech firms, research institutions, and diagnostics companies globally through direct and distributor-partner channels across approximately 60 countries.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	186	259	289	883	799
Cost of revenue	152	151	149	169	141
Gross profit	34	108	140	—	—
Selling, general and administrative	145	162	151	129	100
Research and development	17	19	17	18	15
Change in estimated fair value of contingent consideration	200,000	−2	−3	−8	0
Impairment of goodwill and long-lived assets	69	166	0	—	—
Restructuring	18	−1	6	0	0
Total operating expenses	249	344	172	309	245
Loss from operations	−215	−236	−32	574	555
Interest expense	−27	−48	−46	−20	—
Interest income	11	27	28	2	0
Loss on extinguishment of debt	0	−3	0	−208,000	0
Change in payable to related parties pursuant to the Tax Receivable Agreement	0	−40,000	669	−4	6
Other expense	−4	−2	−1	−358,000	279,000
(Loss) income before income taxes	−235	−261	618	551	531
Income tax (benefit) expense	−4	−2	756	61	62
Net loss	−231	−260	−138	491	469
Net loss attributable to non-controlling interests	−100	−115	−19	270	287
Net loss attributable to Maravai LifeSciences Holdings, Inc.	−131	−145	−119	220	182
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - basic (in usd per share)	−0.9	−1.05	−0.9	1.67	1.59
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - diluted (in usd per share)	−0.9	−1.05	−0.9	1.67	1.56
Weighted average Class A common shares outstandingbasic (in shares)	144	138	132	132	115
Weighted average Class A common shares outstanding - diluted (in shares)	144	138	132	255	258

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-09-30	FY 2024 2024-06-30	FY 2023 2023-12-31
Cash and cash equivalents	217	322	578	573	575
Accounts receivable, net	25	39	29	35	55
Inventory	40	50	51	49	51
Prepaid expenses and other current assets	13	18	22	17	19
Total current assets	296	429	679	682	700
Property and equipment, net	151	164	165	166	163
Goodwill	129	160	172	326	326
Intangible assets, net	152	195	202	207	221
Other assets	42	60	61	63	78
Total assets	771	1,008	1,278	1,444	1,487
Accounts payable	3	12	—	—	—
Accrued expenses and other current liabilities	37	40	39	41	60
Current portion of long-term debt	5	5	5	5	5
Total current liabilities	45	57	64	69	87
Long-term debt, less current portion	286	290	516	517	519
Finance lease liabilities, less current portion	30	31	31	32	32
Other long-term liabilities	36	52	54	54	59
Total liabilities	398	431	666	671	698
Commitments and contingencies (Note 9)	—	—	—	—	—
Additional paid-in capital	199	182	176	168	129
Retained earnings	10	141	167	264	286
Accumulated other comprehensive income	524,000	0	—	—	—
Total stockholders equity attributable to Maravai LifeSciences Holdings, Inc.	212	325	345	435	417
Non-controlling interest	160	252	268	338	373
Total stockholders equity	373	577	613	772	790
Total liabilities and stockholders equity	771	1,008	1,278	1,444	1,487

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	24	21	13	8	6
Amortization of intangible assets	28	28	27	24	18
Amortization of operating lease right-of-use assets	9	8	9	6	9
Amortization of deferred financing costs	2	3	3	3	3
Stock-based compensation expense	30	49	35	19	10
Deferred income taxes	−20,000	11,000	755	42	47
Change in estimated fair value of contingent consideration	0	−2	−3	—	—
Impairment	85	166	0	—	—
Revaluation of liabilities under the Tax Receivable Agreement	0	40,000	−669	4	−6
Acquisition related tax adjustment	4	2	1	349,000	—
Other	212,000	833,000	−4	−8	−281,000
Accounts receivable	13	14	84	−22	−70
Inventory	8	377,000	649,000	9	−22
Prepaid expenses and other current assets	2	2	7	−36	−10
Other assets	181,000	153,000	861,000	—	—
Accounts payable	−7	723,000	5	−2	676,000
Accrued expenses and other current liabilities	−5	−24	15	9	−3
Other long-term liabilities	−19	−6	−16	4	−5
Net cash (used in) provided by operating activities	−58	7	126	536	369
Cash paid for acquisitions of a business, net of cash acquired	−19	0	−70	−239	0
Purchases of property and equipment	−13	−30	−66	−17	−15
Proceeds from government assistance allocated to property and equipment	734,000	7	13	1	0
Other investing activities, net	0	−2	0	—	—
Net cash used in investing activities	−31	−24	−122	−268	106
Refunds (distributions) for tax liabilities to non-controlling interests holder	10,000	−494,000	−10	—	—
Principal repayments of long-term debt	−5	−234	−5	−14	−6
Financing costs paid to acquire long-term debt	0	−1	0	0	0
Proceeds from interest rate cap agreement	1	9	6	0	0
Payments of acquisition related contingent consideration and consideration holdback	−7	0	−10	0	0
Payments pursuant to the Tax Receivable Agreement	0	−7	−42	—	—
Other financing activities, net	−6	−2	−352,000	—	—
Net cash used in financing activities	−16	−236	−61	−187	−159
Effects of exchange rate changes on cash	−32,000	0	0	0	−88,000
Net decrease in cash and cash equivalents	−106	−253	−57	81	315
Cash paid for interest	25	51	44	20	27
Cash (refunded) paid for income taxes, net	−555,000	670,000	−3	23	22
Property and equipment included in accounts payable and accrued expenses	4	3	2	2	2
Accrued receivable for capital expenditures to be reimbursed under a government contract	0	734,000	1	0	0
Right-of-use assets obtained in exchange for finance lease liabilities	0	0	33	0	0
Right-of-use assets obtained in exchange for operating lease liabilities	463,000	1	4	18	0
Fair value of contingent consideration liability recorded in connection with acquisition of a business	0	0	5	8	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is MARAVAI LIFESCIENCES HOLDINGS, INC.'s CIK number?

MARAVAI LIFESCIENCES HOLDINGS, INC.'s SEC CIK number is 0001823239 (1823239). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find MARAVAI LIFESCIENCES HOLDINGS, INC.'s SEC filings?

All of MARAVAI LIFESCIENCES HOLDINGS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did MARAVAI LIFESCIENCES HOLDINGS, INC. last report earnings?

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001823239-26-000022). This is MARAVAI LIFESCIENCES HOLDINGS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is MARAVAI LIFESCIENCES HOLDINGS, INC.'s most recent earnings 8-K?

MARAVAI LIFESCIENCES HOLDINGS, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001823239-26-000022. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View MARAVAI LIFESCIENCES HOLDINGS, INC.'s latest earnings 8-K →
Look up any company's CIK number →